×
About 1,284 results
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
The New England Journal of Medicine; McMurray, J. et. al.

Sep 18th, 2019 - BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 ...

Xeris Pharmaceuticals Receives U.S. Fda Approval For Gvoke™ (Glucagon), The First Ready-to-use Stable Liquid Glucagon For Severe Hypoglycemia
https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon

Sep 9th, 2019 - Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) for GVOKE™ (glucagon) injection, its ready-to-use, room-temperature stable liquid gl...

BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
https://investor.lilly.com/news-releases/news-release-details/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally

Jul 23rd, 2019 - The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, Eli Lilly and Company (NYSE: LLY) announced today. BAQSIMI is the first and only nasally administered glucagon, and it was designed with severe hypoglycemia rescue in mind. It is compact, portable and ready to ...

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
http://care.diabetesjournals.org/content/42/6/1147
Diabetes Care; Danne, T. et. al.

May 31st, 2019 - Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolut...

Hypoglycemia - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK534841/
Mathew, P. et. al.

Feb 28th, 2019 - Hypoglycemia is often defined by a plasma glucose concentration below 70 mg/dL; however, signs and symptoms may not occur until plasma glucose concentrations drop below 55 mg/dL. The symptoms of Whipple's triad have been used to describe hypoglycemia since 1938. For Whipple's triad, the practitioner must first recognize symptoms of hypoglycemia, then obtain low blood glucose, and finally, demo...

Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2019
http://care.diabetesjournals.org/content/42/Supplement_1/S173

Dec 17th, 2018 - In the hospital, both hyperglycemia and hypoglycemia are associated with adverse outcomes, including death. Therefore, inpatient goals should include the prevention of both hyperglycemia and hypoglycemia. Hospitals should promote the shortest safe hospital stay and provide an effective transition out of the hospital that prevents acute complications and readmission.

Hypoglycemia During Therapy of Diabetes
https://www.ncbi.nlm.nih.gov/books/NBK279100/
Spanakis, E. et. al.

Jun 14th, 2018 - Hypoglycemia, caused by treatment with a sulfonylurea, a glinide, or insulin coupled with compromised defenses against the resulting falling plasma glucose concentrations, is the limiting factor in the glycemic management of diabetes. It causes recurrent morbidity in most people with type 1 diabetes mellitus (T1DM) and many with advanced type 2 diabetes mellitus (T2DM) and is sometimes fatal; i...

Metformin: an old but still the best treatment for type 2 diabetes
https://dmsjournal.biomedcentral.com/articles/10.1186/1758-5996-5-6
Diabetology & Metabolic Syndrome;

Feb 4th, 2013 - The management of T2DM requires aggressive treatment to achieve glycemic and cardiovascular risk factor goals. In this setting, metformin, an old and widely accepted first line agent, stands out not only for its antihyperglycemic properties but also for its effects beyond glycemic control such as improvements in endothelial dysfunction, hemostasis and oxidative stress, insulin resistance, lipid...

BAQSIMI (glucagon) nasal powder | A severe low blood sugar and hypoglycemia treatment
https://www.baqsimi.com

BAQSIMI™ is indicated for the treatment of severe hypoglycemia in patients with diabetes ages 4 years and above

Transitions To, From Insulin Degludec Require Careful Follow-Up
https://www.medscape.com/viewarticle/923335

Jan 5th, 2020 - NEW YORK (Reuters Health) - Transitions of patients to and from insulin degludec require close follow-up, including frequent adjustments of insulin doses, to avoid potential hypoglycemia, according to a new report. "One can induce stacking of basal insulins if differences in pharmacokinetics/pharmacodynamics (PK/PD) are ignored," Dr. Boris Draznin of the University of Colorado Anschutz Medical ...

Can insulin plus metformin improve pregnancy outcomes in women with type 2 diabetes?
https://www.mdedge.com/fedprac/article/214703/obstetrics/can-insulin-plus-metformin-improve-pregnancy-outcomes-women-type-2/page/0/1?channel=53

Dec 23rd, 2019 - Currently, the multisite MOMPOD trial (Medical Optimization of Management of T2DM Complicating Pregnancy) is randomizing 950 women to insulin plus 1,000 mg metformin twice daily or insulin plus placebo. The primary outcome of the trial is a composite of pregnancy loss, preterm birth, birth injury, neonatal hypoglycemia, or hyperbilirubinemia.

Endocrine Society Advisory on Minimizing Hypoglycemia in Diabetes
https://www.medscape.com/viewarticle/922771

Dec 16th, 2019 - The Endocrine Society has introduced the first-ever set of quality measures addressing hypoglycemia for older patients with type 2 diabetes. The three new measures focus specifically on hypoglycemia assessment and reduction in adults aged 65 and older with type 2 diabetes in the outpatient setting. They were published online December 11 in the Journal of Clinical Endocrinology and Metabolism by...

Is strict glycemic control meaningless for older adults?
https://www.mdedge.com/clinicianreviews/article/213780/diabetes/strict-glycemic-control-meaningless-older-adults/page/0/3?channel=205

Dec 7th, 2019 - Similarly, in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), the DPP-4 inhibitor did not increase severe hypoglycemia in the subgroup of participants aged 75 years and older. And in several of the recent cardiovascular outcomes trials demonstrating cardiovascular benefit for type 2 diabetes agents, those benefits have been just as robust among older participants, he stre.

Hypoglycemia Safety Initiative: Working With PACT Clinical Pharmacy Specialists to Individualize HbA1c Goals
https://www.mdedge.com/fedprac/article/178890/diabetes/hypoglycemia-safety-initiative-working-pact-clinical-pharmacy/page/0/3

Nov 13th, 2019 - This project’s strengths included the large sample size, appropriate inclusion criteria that identified patients at risk for hypoglycemia, and the use of shared decision making. It was also beneficial to obtain HbA1c levels after a relaxation in therapy for objective outcomes.

Low-Carb Advice in Group Visits Lowers Hypos, Meds in Diabetes
https://www.medscape.com/viewarticle/920835

Nov 4th, 2019 - Advice on low-carbohydrate diets incorporated into group medical visits for patients with difficult to treat type 2 diabetes was associated with less use of diabetes medication and, surprisingly, less hypoglycemia, as well as greater weight loss, compared to group visits without such advice. Both approaches led to a similar improvement in glycemic control, however. William S. Yancy Jr, MD, from...

Severe hypoglycemia, poor glycemic control fuel fracture risk in older patients with type 2 diabetes
https://www.mdedge.com/obgyn/article/211076/osteoporosis/severe-hypoglycemia-poor-glycemic-control-fuel-fracture-risk-older?channel=266
Jeff Craven

Oct 28th, 2019 - Patients with type 2 diabetes and poor glycemic control or severe hypoglycemia may be at greater risk for fracture, according to recent research from a Japanese cohort of older men and postmenopausal women. “The impacts of severe hypoglycemia and poor glycemic control on fractures appeared to be independent,” noted Yuji Komorita, MD, PhD, of the department of medicine and clinical science, Grad.

Severe hypoglycemia, poor glycemic control fuels fracture risk in older diabetic patients
https://www.mdedge.com/obgyn/article/211076/osteoporosis/severe-hypoglycemia-poor-glycemic-control-fuels-fracture-risk?channel=266
Jeff Craven

Oct 28th, 2019 - Patients with type 2 diabetes and poor glycemic control or severe hypoglycemia may be at greater risk for fracture, according to recent research from a Japanese cohort of older men and postmenopausal women. “The impacts of severe hypoglycemia and poor glycemic control on fractures appeared to be independent,” noted Yuji Komorita, MD, PhD, of the department of medicine and clinical science, Grad.

Liver-Directed Mealtime Insulin Benefits Some With Type 1 Diabetes
https://www.medscape.com/viewarticle/920286

Oct 22nd, 2019 - An investigational liver-targeted formulation of fast-acting insulin may help minimize hypoglycemia in patients with poorly controlled type 1 diabetes, new research suggests. Findings regarding Diasome Pharmaceutical Inc's hepatic-directed vesicle (HDV) insulin were published online September 24 in Diabetes Care. The study was conducted by David Klonoff, MD, clinical professor of medicine at th...

EU Panel Backs Nasal Glucagon for Hypoglycemia; Romosozumab for Osteoporosis
https://www.medscape.com/viewarticle/920067

Oct 17th, 2019 - The European Medicines Agency (EMA) Committee for Medicinal Products (CHMP) has recommended approval of the first nasal glucagon product (Baqsimi, Eli Lilly Nederland BV) for treatment of severe hypoglycemia in patients with diabetes aged 4 years and older, according to an agency news release.     The committee also gave a thumbs up to romosozumab (Evenity, UCB Pharma SA) for treatment of postm...

Deprescribing Antidiabetic Drugs: The Crowdsourced Opinion
https://www.medscape.com/viewarticle/919644

Oct 15th, 2019 - The potential challenges in deprescribing antidiabetic drugs in older adults were the focus of a recent case I presented on Medscape. The question I posed was whether to stop or switch any of the patient's diabetes drugs. To recap: The patient was an obese, 85-year-old woman with type 2 diabetes who didn't exercise or follow a healthy diet. She was experiencing regular episodes of mild hypoglyc...